AKRX - Akorn, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.85
-0.10 (-1.44%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close6.95
Open6.92
Bid0.00 x 1000
Ask0.00 x 1300
Day's Range6.74 - 7.00
52 Week Range5.25 - 33.63
Volume1,466,493
Avg. Volume3,754,432
Market Cap859.62M
Beta (3Y Monthly)2.84
PE Ratio (TTM)N/A
EPS (TTM)-1.48
Earnings DateMay 18, 2017 - May 19, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1991-05-24
1y Target Est8.75
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markit6 days ago

    See what the IHS Markit Score report has to say about Akorn Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • GlobeNewswire7 days ago

    Investor Alert - Akorn, Inc. (AKRX) – Kehoe Law Firm, P.C. Investigating Potential Claims Against Certain Officers and Directors of Akorn, Inc.

    Shares of Akorn (AKRX) fell over 48% last month, according to data provided by S&P Global Market Intelligence. The news wasn't that surprising: On the first day of October, a judge ruled that German healthcare giant Fresenius could walk away from its bid to acquire the smaller drug company for $4.75 billion. Further, Motley Fool reported that “.

  • GlobeNewswire11 days ago

    Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Akorn, Inc. (AKRX) and Encourages AKRX Investors to Contact the Firm

    NEW YORK, Nov. 07, 2018 -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Akorn, Inc. (NASDAQ: AKRX). In a recent.

  • Associated Press12 days ago

    Akorn: 3Q Earnings Snapshot

    The Lake Forest, Illinois-based company said it had a loss of 56 cents per share. Losses, adjusted for asset impairment costs and amortization costs, were 6 cents per share. The results did not meet Wall ...

  • GlobeNewswire12 days ago

    Akorn Provides Third Quarter 2018 Results

    LAKE FOREST, Ill., Nov. 06, 2018 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced its financial results for the third quarter.

  • Here's Why Akorn, Inc. Fell 48.6% in October
    Motley Fool14 days ago

    Here's Why Akorn, Inc. Fell 48.6% in October

    A judge gave Fresenius the green light to walk away from the now-infamous merger.

  • GlobeNewswire21 days ago

    Akorn Receives Product Approval

    LAKE FOREST, Ill., Oct. 29, 2018 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, announced that, on October 26, 2018, it received a new.

  • PR Newswire26 days ago

    Resideo Technologies Set to Join S&P MidCap 400; Akorn to Join S&P SmallCap 600

    NEW YORK , Oct. 23, 2018 /PRNewswire/ -- Resideo Technologies Inc. (NYSE: REZI) will replace Akorn Inc. (NASD: AKRX) in the S&P MidCap 400, and Akorn will replace Big 5 Sporting Goods Corp. (NASD: BGFV) ...

  • ACCESSWIRE28 days ago

    Akorn to Press Buyout Lawsuit Further, Extensive Product Line, Analysts Review and Target

    NEW YORK, NY / ACCESSWIRE / October 22, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Akorn, Inc. (AKRX), a generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, branded as well as private-label over-the-counter consumer health products and animal health pharmaceuticals. Akorn is involved in a lawsuit with Fresenius SE for canceling a $4.3 billion buyout of AKRX. AKRX specializes in generic pharmaceutical products in alternative dosage forms.

  • GlobeNewswirelast month

    Akorn Appeals Fresenius Kabi Ruling

    LAKE FOREST, Ill., Oct. 18, 2018 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that the company filed a notice of appeal to.

  • RM LAW Announces Investigation of Akorn, Inc.
    PR Newswirelast month

    RM LAW Announces Investigation of Akorn, Inc.

    BERWYN, Pa. , Oct. 17, 2018 /PRNewswire/ --  RM LAW, P.C. has commenced an investigation into potential securities law violations by certain officers of Akorn, Inc. ("Akorn" or the "Company") ...

  • Benzingalast month

    Akorn Upgraded By Piper Jaffray On Improved Cost Structure, Product Potential

    A closer look at Akorn, Inc. (NASDAQ: AKRX )'s generics business led Piper Jaffray to turn bullish on the drug manufacturer's stock.  The Analyst Analyst David Amsellem upgraded Akorn from Neutral to Overweight ...

  • Moody'slast month

    Akorn, Inc. -- Moody's downgrades Akorn to B3; outlook changed to developing

    Moody's Investors Service ("Moody's") downgraded the ratings of Akorn, Inc. ("Akorn") including the Corporate Family Rating to B3 from B1, the Probability of Default Rating to B3-PD from B1-PD and the senior secured term loan rating to B3 from B1. Moody's also downgraded the Speculative Grade Liquidity Rating to SGL-2 from SGL-1.

  • Implied Volatility Surging for Akorn (AKRX) Stock Options
    Zackslast month

    Implied Volatility Surging for Akorn (AKRX) Stock Options

    Investors need to pay close attention to Akorn (AKRX) stock based on the movements in the options market lately.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Akorn Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Business Wirelast month

    Robbins Arroyo LLP Is Investigating the Officers and Directors of Akorn, Inc. (AKRX) on Behalf of Shareholders

    Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Akorn, Inc. breached their fiduciary duties to shareholders.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Akorn Inc.

    Akorn Inc NASDAQ/NGS:AKRX

  • Benzingalast month

    Akorn's Generic Drug For Inadequate Eye Lashes Receives FDA Nod

    Akorn, Inc. (NASDAQ: AKRX ) shares  — which tumbled roughly 60 percent to $5.36 Oct. 1 on a ruling that Fresenius SE is free to exit its M&A agreement with Akorn —  had a reprieve early Wednesday. What ...

  • MarketWatchlast month

    Akorn's stock soars after FDA approves ANDA for hypotrichosis of eyelashes treatment

    Shares of Akorn Inc. ran up 13% in premarket trade Wednesday, putting them on track for a seventh-straight gain, after the generic drug maker said its new Abbreviated New Drug Application (ANDA) for Bimatoprost Ophthalmic Solution was approved by the Food and Drug Administration. Bimatoprost Ophthalmic Solution is indicated to treat hypotrichosis of the eyelashes. The stock had plummeted 59% on Oct. 1 to a 7 1/2-year closing low, after a court ruled in favor of Germany-based Fresenius SE & Co.'s attempt to end its buyout of Akorn. Since then, the stock has rallied 20.5% amid a six-session win streak through Tuesday. Despite the recent gains, the stock has tumbled 80% year to date through Tuesday, while the S&P 500 has advanced 7.7%.

  • GlobeNewswirelast month

    Akorn Receives Product Approval

    LAKE FOREST, Ill., Oct. 10, 2018 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it has received a new Abbreviated New.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Akorn Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Why Akorn Stock Crashed Yesterday
    Market Realist2 months ago

    Why Akorn Stock Crashed Yesterday

    Akorn stock (AKRX) fell dramatically from $12.98 on September 28 to $5.36 on October 1 after the Delaware Court of Chancery ruled against the company and in favor of Fresenius. The ruling permits Fresenius to terminate the $4.8 billion merger agreement with Akorn. Fresenius has cited data integrity issues in regards to Akorn’s operations as one of the main reasons for the termination of the deal in its press release.